{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:04:46Z","timestamp":1776276286120,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ncl.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T09:31:11Z","timestamp":1694251871000},"page":"115-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies"],"prefix":"10.1016","volume":"42","author":[{"given":"Ahmad","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag"},{"issue":"6","key":"10.1016\/j.ncl.2023.08.002_bib2","first-page":"435","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2023.08.002_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.08.002_bib4","first-page":"CD001331","article-title":"Corticosteroids or ACTH for acute exacerbations in multiple sclerosis","volume":"4","author":"Filippini","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ncl.2023.08.002_bib5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.08.002_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.ncl.2023.08.002_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2990.1980.tb00199.x","article-title":"Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system","volume":"6","author":"Esiri","year":"1980","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7359","key":"10.1016\/j.ncl.2023.08.002_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2023.08.002_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2023.08.002_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ncl.2023.08.002_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"ULTIMATE I and ULTIMATE II Investigators. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib14","article-title":"Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions","volume":"8","author":"Alvarez","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"10","key":"10.1016\/j.ncl.2023.08.002_bib15","first-page":"674","article-title":"Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma","volume":"70","author":"Tachi","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.ncl.2023.08.002_bib16","unstructured":"Ocrevus (ocrelizumab) prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761053s029s030lbl.pdf Accessed August 05, 2022. No abstract available."},{"issue":"6","key":"10.1016\/j.ncl.2023.08.002_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib18","doi-asserted-by":"crossref","first-page":"ofy356","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis","volume":"6","author":"Ciardi","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.08.002_bib21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurol"},{"issue":"25","key":"10.1016\/j.ncl.2023.08.002_bib23","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.08.002_bib25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/acn3.51111","article-title":"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib26","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"9856","key":"10.1016\/j.ncl.2023.08.002_bib27","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta\u00a01a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.ncl.2023.08.002_bib28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ncl.2023.08.002_bib29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.08.002_bib30","unstructured":"Lemtrada (alemtuzumab) prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/103948s5185lbl.pdf (Accessed on June 17, 2022)."},{"key":"10.1016\/j.ncl.2023.08.002_bib31","unstructured":"European Medicines Agency. Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en-0.pdf Accessed on May 05, 2020."},{"key":"10.1016\/j.ncl.2023.08.002_bib32","unstructured":"FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm624247.htm Accessed on November 29, 2018."},{"issue":"4","key":"10.1016\/j.ncl.2023.08.002_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(19)30076-6","article-title":"Intracerebral haemorrhage during alemtuzumab administration","volume":"18","author":"Azevedo","year":"2019","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2023.08.002_bib34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ncl.2023.08.002_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2023.08.002_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421993999","article-title":"Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"14","author":"Wundes","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.ncl.2023.08.002_bib37","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study","volume":"39","author":"Wray","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.ncl.2023.08.002_bib38","doi-asserted-by":"crossref","first-page":"116498","DOI":"10.1016\/j.jns.2019.116498","article-title":"Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up","volume":"407","author":"Vollmer","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib40","article-title":"Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics","volume":"8","author":"Hersh","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"10.1016\/j.ncl.2023.08.002_bib41","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/art.21255","article-title":"Disruption of the interaction of T\u00a0cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation","volume":"52","author":"Zeyda","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"14","key":"10.1016\/j.ncl.2023.08.002_bib42","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2023.08.002_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10306","key":"10.1016\/j.ncl.2023.08.002_bib44","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2023.08.002_bib46","doi-asserted-by":"crossref","first-page":"104425","DOI":"10.1016\/j.msard.2022.104425","article-title":"The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination","volume":"69","author":"Baker","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A\u00a0placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ncl.2023.08.002_bib48","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2023.08.002_bib49","unstructured":"Prescribing information Mavenclad (cladribine) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022561s006lbl.pdf Accessed on October 20, 2022."},{"issue":"9","key":"10.1016\/j.ncl.2023.08.002_bib50","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.yexcr.2011.03.002","article-title":"Beta-interferon for multiple sclerosis","volume":"317","author":"Rudick","year":"2011","journal-title":"Exp Cell Res"},{"issue":"9316","key":"10.1016\/j.ncl.2023.08.002_bib51","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2023.08.002_bib52","doi-asserted-by":"crossref","first-page":"14593","DOI":"10.1073\/pnas.0404887101","article-title":"Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications","volume":"101","author":"Arnon","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"10","key":"10.1016\/j.ncl.2023.08.002_bib53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.ncl.2023.08.002_bib54","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458518800827","article-title":"Current advancements in promoting remyelination in multiple sclerosis","volume":"25","author":"Kremer","year":"2019","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.msard.2014.05.003","article-title":"Risk stratification and mitigation multiple sclerosis","volume":"3","author":"Ontaneda","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"DISCOMS investigators. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2023.08.002_bib58","doi-asserted-by":"crossref","first-page":"799138","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.08.002_bib59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.08.002_bib60","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.08.002_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2023.08.002_bib62","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat Med"},{"issue":"10111","key":"10.1016\/j.ncl.2023.08.002_bib63","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ncl.2023.08.002_bib64","first-page":"304","article-title":"Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study","volume":"264","author":"Schwartzbach","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.08.002_bib65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nn1460","article-title":"LINGO-1 negatively regulates myelination by oligodendrocytes","volume":"8","author":"Mi","year":"2005","journal-title":"Nat Neurosci"},{"issue":"7","key":"10.1016\/j.ncl.2023.08.002_bib66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40263-013-0068-8","article-title":"Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic","volume":"27","author":"Mi","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ncl.2023.08.002_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12016-009-8170-x","article-title":"The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation","volume":"39","author":"Perron","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.ncl.2023.08.002_bib68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ana.23970","article-title":"Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation","volume":"74","author":"Kremer","year":"2013","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2023.08.002_bib69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon \u03b2-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"Lancet Neurol"},{"issue":"9936","key":"10.1016\/j.ncl.2023.08.002_bib70","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"issue":"Pt B","key":"10.1016\/j.ncl.2023.08.002_bib71","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacology"},{"issue":"13","key":"10.1016\/j.ncl.2023.08.002_bib72","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ncl.2023.08.002_bib73","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1507\/endocrj1954.27.521","article-title":"Effects of domperidone on serum prolactin levels in human beings","volume":"27","author":"Fujino","year":"1980","journal-title":"Endocrinol Jpn"},{"issue":"8","key":"10.1016\/j.ncl.2023.08.002_bib74","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1523\/JNEUROSCI.4441-06.2007","article-title":"White matter plasticity and enhanced remyelination in the maternal CNS","volume":"27","author":"Gregg","year":"2007","journal-title":"J\u00a0Neurosci"},{"issue":"2","key":"10.1016\/j.ncl.2023.08.002_bib75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.26503","article-title":"Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants","volume":"93","author":"Kalluri","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2023.08.002_bib76","unstructured":"Cree BA, Ziemann A, Pfleeger K, Schwefel B, Wundes A, Freedman MS. Safety and Efficacy of Elezanumab in Relapsing and Progressive Forms of Multiple Sclerosis: Results From Two Phase 2 Studies, RADIUS-R and RADIUS-P. OP149, ECTRIMS 2021 Virtual Congress, 13\u201315 October."}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861923000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861923000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:21:32Z","timestamp":1760005292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861923000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0733861923000828"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2023.08.002","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}